Dopamine receptor agonists antiparkinsonian

Administration of levodopa plus carbidopa (or benserazide) remains the most effective treatment, but does not provide benefit beyond 3-5 y and is followed by gradual loss of symptom control, on-off fluctuations, and development of orobuccofacial and limb dyskinesias. These long-term drawbacks of levodopa therapy may be delayed by early monotherapy with dopamine receptor agonists. Treatment of advanced disease requires the combined administration of antiparkinsonian agents. 

Bromocriptine (Parl el) [Antiparkinsonian Agent/Dopamine Receptor Agonist] Uses Parkin on Dz, hyperprolactinemia, acromegaly, pituitary tumors Action Direct-acting on the striatal dopamine receptors X prolactin secretion Dose Initial, 1.25 mg PO bid titrate to effect, w/ food Caution [B, ] Contra Severe ischemic heart Dz or PVD Disp Tabs, caps SE X BP, Raynaud phenomenon (vasospastic disorder resulting in discoloration of the fmgers/toes), dizziness, N, hallucinations Interactions T Effects W/ erythromycin, fluvoxamine, nefazodone, sympathomimetics, antihypertensives X effects W/ phenothiazines, antipsychotics EMS Monitor BP may cause intolerance to EtOH OD May cause NA, severe hypotension give IV fluids symptomatic and supportive... 

Intropin ) is a catecholamine that occurs in the mammalian CNS, in several higher plants and alga. It is a major central neurotransmitter, a dopamine receptor agonist and a SYMPATHOMIMETIC, with predominantly (Pi-subtype) p-ADRENOCEPTOR AGONIST actions. It Can be used as a cardiac STIMULANT and ANTIHYPOTENSIVE in cardiogenic hypotension. Its precursor amino acid, levodopa, is used as an ANTIPARKINSONIAN AGENT. 

Bromocriptine, a dopaminomimetic that is a dopamine D2 receptor agonist, possesses expressed antiparkinsonian activity. It is used for treating all phases of idiopathic and post-encephalic Parkinsonism. However, it has a number of undesirable side effects, even causing mental disturbances in long-term use. The most common synonyms are parlodel, bromergon, and others. 

Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD (1988) The D-l dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 756 197-206. 

Antiparkinsonian agents. In Parkinson disease, nigrostriatal dopamine neurons degenerate. To compensate for the lack of dopamine, use is made of L-dopa as the dopamine precursor and of D2 receptor agonists (cf. 

Mechanism of Action A dopaminergic agonist that blocks the uncoating of influenza A virus, preventing penetration into the host and inhibiting M2 protein in the assembly of progeny virions. Amantadine also blocks the reuptake of dopamine into presyn-aptic neurons and causes direct stimulation of postsynaptic receptors. Therapeutic Effect Antiviral and antiparkinsonian activity. 

Kitamura Y, Taniguchi T, Shimohama S et al. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res 2003 28 1035-1040. 

---